Perceptions of herceptin®: A monoclonal antibody for the treatment of breast cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 14, Issue 1, 1999, Pages 5-10

  Dillman, Robert O ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EDRECOLOMAB; MONOCLONAL ANTIBODY; PACLITAXEL; RITUXIMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CANCER ANTIBODY; CYTOKINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HYBRID PROTEIN; TUMOR PROTEIN;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY COMPLEX; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST ADENOCARCINOMA; BREAST CANCER; CANCER IMMUNOTHERAPY; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COUGHING; DRUG APPROVAL; DRUG INDICATION; FEVER; GENE OVEREXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MULTIMODALITY CANCER THERAPY; NAUSEA; PRIORITY JOURNAL; RECEPTOR BLOCKING; TREATMENT OUTCOME; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; CARDIOMYOPATHY; DYSPNEA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; IMMUNOTHERAPY; MOUSE; PAIN; PROTO ONCOGENE; PSYCHOLOGICAL ASPECT; REVIEW; SECRETION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, NEOPLASM; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARDIOMYOPATHIES; COMBINED MODALITY THERAPY; CYTOKINES; DYSPNEA; FEMALE; FEVER; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASM PROTEINS; PAIN; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS;

EID: 0032586389     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1999.14.5     Document Type: Article

References (28)

1. Dillman RO. Monoclonal antibodies for treating cancer. Ann Intern Med 1989;111:592-603.
2. Dillman RO. Magic bullets at last! Finally - approval of a monoclonal antibody for the treatment of cancer!!! Cancer Biother Radiopharm 1997;12:223-225.
3. McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Breckler I, White CA, Cabanillas F, Jain V, Ho AD, Lister J, Wey K, Shen D, Dallaire BK. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1988; 16:2825-2833.
4. Coiffier B, Haioun C, Ketterer N, Engert A, Tillly H, Ma D, Johnson P, Lister A, Feuring-Buske M, Radford JA, Capdeville R, Diehl V, Reyes F. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92: 1927-1932.
5. Czuczman M, Grillo-Lopez AJ, White CA, Saleh M, Gordon L, LoBuglio AF, Jonas C, Dallaire B, Varns C. IDEC-C2B8/CHOP chemoimmunotherapy in patients with low-grade lymphoma: clinical and BCL-2 (PCR) results. Blood 1996;88 (no 10, suppl 1):453a.
6. Link B, Grossbard ML, Fisher RI, Czuczman M, Gilman P, Lowed AM, Vose JM. Phase II pilot study of the safety and efficacy of Rituximab in combination with CHOP chemotherapy in patients with previously untreated intermediate-or high-grade NHL. Proc Am Soc Clin Oncol 1998;17:3a.
7. Genentech Product Information, 1998.
8. Coussens L, Yang-Feng TI, Liao YC, Chen E, ray A, McGrath J, Seeburg PH, Libermann TA, Schlessinger J, Francke U, et al. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 1985;230:1132-1139.
9. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udov J, Ullrich A, et al. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer. Science 1989; 244:707-712.
10. Tommasi S, Paradiso A, Mangia A, Barletta A, Simone G, Slamon DJ, DeLena M. Biological correlation between HER-2/neu and proliferative activity in human breast cancer. Anticancer Res 1991;11:1395-1400.
11. Press MF, Pike MC, Chazin VR, Hung G, Udove JA, Markowicz M, Danyluk J, Godolphis W, Sliwkowski M, Akita R, et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. Cancer Res 1993;53:4960-4970.
12. HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 1989;9:1165-1172.
13. Klapper LN, Vaisman N, Hurwitz E, Pinkas-Kramarski R, Yarden Y, Sela M. A subclass of tumor-inhibitory monoclonal antibodies to ErbB2/HER2 blocks crosstalk with growth factor receptors. Oncogene 1997;14:2099-2109.
14. Hotaling TE, Reitz B, Wolfgang-Kimball D, Bauer K, Fox JA. The humanized anti-HER2 antibody rhuMAb HER2 mediates antibody dependent cell-mediated cytotoxicity via FcΥR III. Proc Am Assoc Cancer Res 1996;37:471.
15. Baselga J, Tripathy D, Mendelsohn J, Baughman S, Benz CC, Dantis L, Sklarin NT, Seidman AD, Hudis CA, Moore J, Rosen PP, Twaddell T, Henderson IC, Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-744.
16. Pegram MD, Lipton A, Haves DF, Weber BL, Baselga JM, Tripathy D, Baly D, Bauthman SA, Twaddell T, Glaspy JA, Slamon DJ. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus Cisplatin in patients with HER2/neu overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-2671.
17. Baselga JU, Norton L, Albanell J, Kim YM, Mendelsohn J. Recombinant humanized anti-HER2 antibody (Herceptin®) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 1998; 58:2825-2831.
18. Dillman RO, Beauregard JC, Jamieson M, Amox D, Hlpern SE. Toxicities associated with monoclonal antibody infusions in cancer patients. Molec Biother 1988;1:81-85.
19. Winkler U, Jensen M, Manzke O, Tesch H, Bohlen H, Diehl V, Engert A, et al. Severe side effects in patients with B-cell chronic lymphocytic leukemia and lymphocytosis treated with the monoclonal anti-CD20 antibody Rituximab. Blood 92 (no 10, suppl 1):285b, 1998
20. Lee KS: Requirement for neuroregulin receptor, erbB2, in neural and cardiac development. Nature 1995;379: 394-396.
21. Dillman RO, Shawler DL, Johnson DE, Meyer DL, Koziol JA, Frincke JE. Preclinical trials with combinations and conjugates of T101 and doxorubicin. Cancer Res 1986;46:4886-4891.
22. Dillman RO, Johnson DE, Ogden JR, Beidler D. Significance of antigen, drug and tumor cell targets in the preclinical evaluation of doxorubicin, daunorubicin, methotrexate, and mitomycin-C monoclonal antibody immunoconjugates. Molec Biother 1989;1:250-255.
23. Meden H, Kuhn W. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: a new prognostic factor. Eur J Obstet Gynecol Reprod Biol 1997;71: 173-179.
24. Lyne JV, Melhem MF, Finley GG, Wen D, Liu N, Deng DH, Salup R. Tissue expression of neu differentiation factor/heregulin and its receptor complex in prostate cancer and its biologic effects on prostate cancer cells in vitro. Cancer J Sci Am 1997;3:212-30.
25. Peiper M, Goedegebuure PS, Linehan DC, Ganguly E, Douville CC, Eberlein TJ. The Her2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes. Eur J Immunol 1997;27:115-1123.
26. Sears HF, Herlyn D, Steplewski Z, Koprowski H. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma. Cancer Res 1985; 45:5910-5913.
27. Riethmuller G, Schneider-Gadicke E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Gruber R, Pichlmaier H, Furche H, Pichlmayr R, et al. Randomized trial of monoclonal antibody for adjuvant therapy of resected Dukes'C colorectal cancer. Lancet 1994;343:1177-1183.
28. Riethmuller G, Holz E, Schlimok G, Schmiegel W, Raab R, Hoffken K, Bruger R, Runke I, Pichlmaier H, Hirche H, Buggisch P, Witte J, Pichlmayr R, et al. Monoclonal antibody therapy for resected Dukes'C colorectal cancer: seven-year outcome of a multicenter randomized trial. J Clin Oncol 1998;16:1788-1794.